ANI Pharmaceuticals (NASDAQ:ANIP) Given Buy Rating at Guggenheim

Guggenheim reiterated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report released on Tuesday morning, Benzinga reports. Guggenheim currently has a $77.00 price target on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. HC Wainwright raised their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a buy rating in a research note on Monday, March 4th. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a buy rating in a research note on Friday, March 1st. Finally, Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an overweight rating and a $80.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of Buy and an average target price of $80.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $65.36 on Tuesday. The firm has a 50-day moving average of $65.68 and a 200-day moving average of $58.84. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81. The company has a market cap of $1.38 billion, a PE ratio of 77.81 and a beta of 0.79. ANI Pharmaceuticals has a one year low of $37.06 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. As a group, equities analysts forecast that ANI Pharmaceuticals will post 3.55 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Muthusamy Shanmugam sold 7,414 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $66.33, for a total value of $491,770.62. Following the completion of the transaction, the chief operating officer now directly owns 825,206 shares in the company, valued at approximately $54,735,913.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Nikhil Lalwani sold 28,965 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total value of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at approximately $29,155,155.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Muthusamy Shanmugam sold 7,414 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $66.33, for a total transaction of $491,770.62. Following the completion of the transaction, the chief operating officer now owns 825,206 shares of the company’s stock, valued at $54,735,913.98. The disclosure for this sale can be found here. Insiders sold 156,803 shares of company stock worth $10,363,466 in the last quarter. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Global Alpha Capital Management Ltd. raised its position in shares of ANI Pharmaceuticals by 15.9% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 525,528 shares of the specialty pharmaceutical company’s stock valued at $30,512,000 after buying an additional 72,200 shares in the last quarter. ClariVest Asset Management LLC grew its holdings in shares of ANI Pharmaceuticals by 36.7% during the 3rd quarter. ClariVest Asset Management LLC now owns 51,338 shares of the specialty pharmaceutical company’s stock valued at $2,980,000 after purchasing an additional 13,792 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of ANI Pharmaceuticals by 287.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 146,989 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after purchasing an additional 109,015 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter valued at approximately $685,000. Finally, EAM Investors LLC bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter valued at approximately $1,489,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.